Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2023-04-01
2024-03-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High Neutrophil-to-Lymphocyte Ratio and Patients With Hemodialysis
NCT07070557
Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio to Predict Carotid Intima-Media Thickness in Chronic Kidney Disease Patients
NCT05472805
Frequency and Risk Factors of Bleeding in Patients With Chronic Kidney Disease Receiving Anticoagulants
NCT06543927
Studying the Relationship Between Mean Platelet Volume and Neutrophil/ Lymphocyte Ratio With Inflammation and Proteinuria in Chronic Kidney Disease
NCT03149068
Neutrophil-to-Lymphocyte and Platelet-to-lymphocyte Ratios as a Predictor Factors for Chronic Kidney Disease Progression
NCT06670599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1-CKD patients without cardiovascular complications
RDW to platlet count ratio
RDW to platlet ratio will be measured for all patients and results will be compared between groups
2-CKD patients with cardiovascular complications
RDW to platlet count ratio
RDW to platlet ratio will be measured for all patients and results will be compared between groups
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RDW to platlet count ratio
RDW to platlet ratio will be measured for all patients and results will be compared between groups
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients who had previously undergone kidney transplantation .
* CKD patients with history of previous CVD
* patients with an infection, blood transfusion or receiving immunosuppressive drugs, as this may have affected the inflammatory response within the 3 months
* patients who were pregnant
* patients with chronic hematological disease
* patient\<18 years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doha Aly Mohamed
Dr
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Ali M Kassem
Role: CONTACT
References
Explore related publications, articles, or registry entries linked to this study.
Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021 Mar 16;143(11):1157-1172. doi: 10.1161/CIRCULATIONAHA.120.050686. Epub 2021 Mar 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CKD and CV complications
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.